Assembly Biosciences (NASDAQ:ASMB) Lowered to Hold Rating by StockNews.com

Assembly Biosciences (NASDAQ:ASMB) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Monday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research report on Monday.

Assembly Biosciences Stock Performance

Shares of NASDAQ ASMB traded up $0.11 during midday trading on Monday, reaching $11.12. The company’s stock had a trading volume of 25,324 shares, compared to its average volume of 24,453. The company has a market cap of $70.68 million, a P/E ratio of -1.65 and a beta of 0.62. The business’s 50 day moving average price is $12.84 and its two-hundred day moving average price is $15.09. Assembly Biosciences has a fifty-two week low of $10.27 and a fifty-two week high of $19.93.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, beating the consensus estimate of ($1.75) by $0.18. The firm had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. Sell-side analysts forecast that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Assembly Biosciences

In other Assembly Biosciences news, Director Michael Houghton bought 3,202 shares of Assembly Biosciences stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $15.61 per share, with a total value of $49,983.22. Following the acquisition, the director now owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently modified their holdings of the business. FMR LLC grew its position in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 3,635 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares during the last quarter. Peapod Lane Capital LLC bought a new position in Assembly Biosciences in the 4th quarter valued at approximately $994,000. Palumbo Wealth Management LLC acquired a new stake in Assembly Biosciences in the fourth quarter valued at approximately $180,000. Finally, Monimus Capital Management LP acquired a new stake in Assembly Biosciences in the fourth quarter valued at approximately $664,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.